{"id":"doi:10.18632/oncotarget.8169","kind":"article","title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","authors":["Böger C","Behrens HM","Mathiak M","Krüger S","Kalthoff H","Röcken C"],"author_count":6,"year":2016,"published":"2016-04-01","venue":"Oncotarget","cited_by":236,"doi":"10.18632/oncotarget.8169","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.18632/oncotarget.8169","archive_url":"https://space-kitty.com/papers/doi:10.18632/oncotarget.8169","updated":null,"pmid":"27009855","pmcid":"PMC5029700","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC5029700/pdf","abstract":"Targeting the PD-1/PD-L1 immune checkpoint signaling is a novel promising treatment strategy in several tumor entities, and it is suggested that PD-L1/PD-1 expression is predictive for a PD-1/PD-L1 checkpoint inhibitor treatment response. We investigated the expression of PD-L1 and PD-1 by immunohistochemistry in a large and well characterized gastric cancer (GC) cohort of Caucasian patients, consisting of 465 GC samples and 15 corresponding liver metastases. Staining results were correlated with clinico-pathological characteristics and survival. PD-L1 expression was found in tumor cells of 140 GCs (30.1%) and 9 liver metastases (60%) respectively in immune cells of 411 GCs (88.4%) and 11 liver metastases (73.3%). PD-1 was expressed in tumor infiltrating lymphocytes in 250 GCs (53.8%) and in 11 liver metastases (73.3%). PD-L1 expression was significantly more prevalent in men, GCs of the proximal stomach, unclassified, papillary, Her2/neu-positive, Epstein-Barr-virus-positive, microsatellite instable, and PIK3CA-mutated GCs. A high PD-L1/PD-1 expression was associated with a significantly better patient outcome, and PD-L1 turned out to be an independent survival prognosticator. The correlation of PD-L1/PD-1 expression with distinct clinico-pathological patient characteristics may serve as a surrogate marker of PD-L1-positive GCs and may direct the use of immune checkpoint treatment strategies.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients\" by Böger C, Behrens HM, Mathiak M et al., https://doi.org/10.18632/oncotarget.8169, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}